MNOVMEDICINOVA INC

Nasdaq medicinova.com


$ 1.32 $ -0.07 (-5.07 %)    

Friday, 03-May-2024 15:59:52 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 1.31
$ 1.35
$ 1.30 x 100
$ 1.34 x 100
$ 1.30 - $ 1.36
$ 1.26 - $ 2.66
19,992
na
64.25M
$ 1.35
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-15-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 02-16-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 02-16-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 02-19-2021 12-31-2020 10-K
14 10-26-2020 09-30-2020 10-Q
15 07-28-2020 06-30-2020 10-Q
16 04-23-2020 03-31-2020 10-Q
17 02-13-2020 12-31-2019 10-K
18 10-25-2019 09-30-2019 10-Q
19 07-25-2019 06-30-2019 10-Q
20 04-25-2019 03-31-2019 10-Q
21 02-13-2019 12-31-2018 10-K
22 10-25-2018 09-30-2018 10-Q
23 07-23-2018 06-30-2018 10-Q
24 04-25-2018 03-31-2018 10-Q
25 02-13-2018 12-31-2017 10-K
26 10-23-2017 09-30-2017 10-Q
27 07-26-2017 06-30-2017 10-Q
28 04-26-2017 03-31-2017 10-Q
29 02-14-2017 12-31-2016 10-K
30 10-25-2016 09-30-2016 10-Q
31 07-26-2016 06-30-2016 10-Q
32 04-27-2016 03-31-2016 10-Q
33 02-25-2016 12-31-2015 10-K
34 10-29-2015 09-30-2015 10-Q
35 07-30-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 03-12-2015 12-31-2014 10-K
38 11-13-2014 09-30-2014 10-Q
39 08-13-2014 06-30-2014 10-Q
40 05-08-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reported-earlier-medicinova-announces-abstract-regarding-results-of-a-clinical-trial-of-mn-166-in-glioblastoma-accepted-for-presentation-at-the-2024-asco

Abstract Number: 2106 Title:  Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients ...

 why-mariadb-shares-are-trading-higher-by-around-100-here-are-20-stocks-moving-premarket

Shares of MariaDB plc (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announce...

 reported-earlier-medicinova-receives-notice-of-allowance-from-japan-patent-office-for-mn-166-in-macular-injury-treatment

Once issued, this patent is expected to expire no earlier than October 2039.  The allowed claims cover the use of MN-166 (ibudi...

 reported-earlier-medicinova-announces-two-abstracts-regarding-mn-001-and-mn-002-accepted-for-presentation-at-the-92nd-eas-2024-congress

 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the ...

 why-renew-energy-global-shares-are-trading-higher-by-around-14-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy ...

 why-is-neuro-oncology-focused-medicinova-stock-trading-higher-today

MediciNova Inc's (NASDAQ: MNOV) collaborators presented new data and results of a Phase 2 clinical trial of MN-166 (ibudila...

 why-applied-uv-shares-are-trading-higher-by-around-96-here-are-20-stocks-moving-premarket

Shares of Applied UV, Inc. (NASDAQ: AUVI) shares jumped in pre-market trading after the company reported third-quarter results.

 medicinova-announces-new-data-and-results-of-a-phase-2-clinical-trial-of-mn-166-in-glioblastoma-presented-at-the-28th-annual-meeting-of-the-society-for-neuro-oncology

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the T...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION